Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBT Margin (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBT Margin for 3 consecutive years, with 164.92% as the latest value for Q1 2025.

  • On a quarterly basis, EBT Margin changed N/A to 164.92% in Q1 2025 year-over-year; TTM through Sep 2025 was 1595.38%, a 775596.0% decrease, with the full-year FY2023 number at 2570.28%, changed N/A from a year prior.
  • EBT Margin was 164.92% for Q1 2025 at Centessa Pharmaceuticals, down from 1388.83% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 3913.07% in Q2 2022 to a low of 164.92% in Q1 2025.
  • A 3-year average of 2147.71% and a median of 1997.43% in 2023 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was -60195bps in 2023; the steepest drop was -191564bps in 2023.
  • Centessa Pharmaceuticals' EBT Margin stood at 1990.78% in 2022, then plummeted by -30bps to 1388.83% in 2023, then plummeted by -112bps to 164.92% in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBT Margin are 164.92% (Q1 2025), 1388.83% (Q4 2023), and 1632.19% (Q3 2023).